Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)today is providing further information regarding a previously communicated voluntary recall of two lots of Soliris ® (eculizumab) Concentrated Solution for Intravenous Infusion. As stated on Nov. 12, 2013, the two lots were found to contain visible particles. At that time, Alexion provided instructions to return any unused vials of Soliris from these two lots at the distributor level. Alexion is now providing the same instructions at the hospital/user level.
|Product||Lot||Expiration Date||First Ship Date||Last Ship Date|
|Soliris® (eculizumab) 300 mg/30 mL Concentrated solution for intravenous infusion only NDC 25682-001-01||10010A||Oct. 31, 2015||Oct. 11, 2013||Nov. 1, 2013|
|10001-1||July 31, 2014||June 4, 2012||May 8, 2013|